WO2020180146A1 - 당뇨망막병증 진단용 복합 마커 및 이의 용도 - Google Patents
당뇨망막병증 진단용 복합 마커 및 이의 용도 Download PDFInfo
- Publication number
- WO2020180146A1 WO2020180146A1 PCT/KR2020/003168 KR2020003168W WO2020180146A1 WO 2020180146 A1 WO2020180146 A1 WO 2020180146A1 KR 2020003168 W KR2020003168 W KR 2020003168W WO 2020180146 A1 WO2020180146 A1 WO 2020180146A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetic retinopathy
- protein
- diagnosis
- marker
- kit
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Definitions
- the present invention relates to a composite marker for diabetic retinopathy diagnosis and a use thereof, and more particularly, to a composite for diabetic retinopathy diagnosis with increased diagnostic performance consisting of two or more blood markers specific for diabetic retinopathy diagnosis. It's about the marker.
- it relates to a composition for diagnosing diabetic retinopathy using the composite marker, a diagnostic kit, and a method of providing information necessary for diabetic retinopathy diagnosis.
- Diabetic retinopathy is a typical complication of diabetes that occurs when microvessels of the retina are damaged, and is one of the three major blind diseases in ophthalmology along with age-related macular degeneration and glaucoma.
- DR Diabetic retinopathy
- the number of diabetic patients increased by 21% from about 2 million in 2012 to about 2.45 million in 2016, but the number of diabetic retinopathy was 38% from about 260,000 in 2012 to 336,000 in 2016. Increased to, and the increase was greater than that of diabetes.
- Diabetic retinopathy occurs because abnormally new blood vessels are formed in this area, causing bleeding without normal blood vessel function.
- Diabetic retinopathy is classified into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) according to its severity. In addition, NPDR is classified into mild, moderate, and severe NPDR according to its degree.
- Nonproliferative diabetic retinopathy shows retinal bleeding, microvascular perfusion, and cotton patches, but maintains good vision until late.
- proliferative diabetic retinopathy new blood vessels are formed in the retina, and if these blood vessels rupture, it causes severe bleeding in the vitreous cavity. It is absorbed over time, but becomes a fibrous tissue, which in turn causes tractional retinal detachment and rebleeding. Leads to blindness.
- Diabetic retinopathy is difficult to diagnose early because there are few initial symptoms, and when symptoms (vision loss, loss of focus, glare) are in progress, the disease has already progressed, and despite treatment (laser, vitreous surgery), it leads to blindness. There are many patients. However, the need for early detection and suppression of diabetic retinopathy and early treatment for high-risk groups is emerging, since it is possible to maintain visual acuity if appropriate treatment is received at the beginning of the onset and blood sugar management is thorough. However, the exact etiology has not yet been identified, and biomarkers that determine the progression of retinopathy have very limited problems.
- the present inventors discovered blood protein markers with high sensitivity and specificity, and tried to improve the early diagnosis ability of diabetic retinopathy by using them in combination.
- MBL2 mannose-binding protein C
- PNLIP pancreatic triacylglycerol lipase
- LGALS3BP glycosylglycerol lipase
- IGFBP2 insulin like growth factor binding protein 2
- An object of the present invention is to provide a complex marker for diabetic retinopathy diagnosis comprising a blood marker specific for diabetic retinopathy diagnosis.
- Another object of the present invention is to provide a composition or a diagnostic kit for diabetic retinopathy using the complex marker for diabetic retinopathy diagnosis.
- Another object of the present invention is to provide a method of providing information necessary for diabetic retinopathy diagnosis using the complex marker for diabetic retinopathy diagnosis.
- the present invention provides a complex marker for diabetic retinopathy diagnosis including manose-binding protein C (MBL2), pancreatic triacylglycerol lipase (PNLIP), galectin-3-binding protein (LGALS3BP), and insulin like growth factor binding protein 2 (IGFBP2). do.
- MBL2 manose-binding protein C
- PNLIP pancreatic triacylglycerol lipase
- LGALS3BP galectin-3-binding protein
- IGFBP2 insulin like growth factor binding protein 2
- the complex markers are ADAMTSL2 (ADAMTS-like protein 2), Cp (Ceruloplasmin), CFH (complement factor H), DDI2 (Protein DDI1 homolog2), FCN2 (Ficolin 2), SELE ( E-selectin), SIGLEC14 (Sialic acid-binding Ig-like lectin 14), THBS1 (Thrombospondin-1), and ZG16B (Zymogen granule protein 16 homolog B) may further include one or more markers selected from the group consisting of. .
- the present invention is a complex marker for diabetic retinopathy diagnosis including manose-binding protein C (MBL2), pancreatic triacylglycerol lipase (PNLIP), galectin-3-binding protein (LGALS3BP), and insulin like growth factor binding protein 2 (IGFBP2) It provides a composition for diabetic retinopathy diagnosis comprising an agent for measuring the level of mRNA or protein.
- MBL2 manose-binding protein C
- PNLIP pancreatic triacylglycerol lipase
- LGALS3BP galectin-3-binding protein
- IGFBP2 insulin like growth factor binding protein 2
- the complex marker is ADAMTSL2 (ADAMTS-like protein 2), Cp (Ceruloplasmin), CFH (complement factor H), DDI2 (Protein DDI1 homolog2), FCN2 (Ficolin 2), SELE ( E-selectin), SIGLEC14 (Sialic acid-binding Ig-like lectin 14), THBS1 (Thrombospondin-1), and ZG16B (Zymogen granule protein 16 homolog B) may further include one or more markers selected from the group consisting of. .
- the agent for measuring the mRNA level of the complex marker may be a primer pair, a probe, or an antisense nucleotide that specifically binds to the gene of the marker.
- the agent for measuring the protein level of the complex marker is an antibody, interacting protein, ligand, nanoparticles or aptamer that specifically binds to the protein or peptide fragment. (aptamer) may be included.
- the present invention provides a diagnostic kit for diabetic retinopathy comprising the composition for diabetic retinopathy diagnosis.
- the kit is a reverse transcription polymerase chain reaction (RT-PCR) kit, a DNA chip kit, an ELISA (Enzyme linked immunosorbent assay) kit, a protein chip kit, a rapid kit, or an MRM ( Multiple reaction monitoring) kit.
- RT-PCR reverse transcription polymerase chain reaction
- DNA chip kit a DNA chip kit
- ELISA Enzyme linked immunosorbent assay
- protein chip kit a protein chip kit
- rapid kit a rapid kit
- MRM Multiple reaction monitoring
- the present invention (a) MBL2 (mannose-binding protein C), PNLIP (pancreatic triacylglycerol lipase), LGALS3BP (galectin-3-binding protein) and IGFBP2 (insulin like growth factor binding protein 2) from biological samples. Measuring the mRNA or protein level of the complex marker for diabetic retinopathy diagnosis comprising; And
- It provides a method for providing information for diabetic retinopathy diagnosis comprising; (b) comparing the mRNA or protein expression level with a control sample.
- the complex marker is ADAMTSL2 (ADAMTS-like protein 2), Cp (Ceruloplasmin), CFH (complement factor H), DDI2 (Protein DDI1 homolog2), FCN2 (Ficolin 2), SELE ( E-selectin), SIGLEC14 (Sialic acid-binding Ig-like lectin 14), THBS1 (Thrombospondin-1), and ZG16B (Zymogen granule protein 16 homolog B) may further include one or more markers selected from the group consisting of. .
- the method of providing information for diabetic retinopathy is the patient's age, body mass index (BMI), smoking, Hb1Ac test results, insulin treatment, hypertension, hyperlipidemia, and One or more clinical information selected from the group consisting of cardiovascular disease may be additionally included and compared with the control group.
- the method of providing information for diabetic retinopathy further comprises determining that the gene expression level or the protein expression level of the complex marker is increased compared to the control group, determining that it is diabetic retinopathy. can do.
- the mRNA expression level is measured using reverse transcriptase polymerase reaction, competitive reverse transcriptase polymerase reaction, real-time reverse transcriptase polymerase reaction, RNase protection assay, Northern blotting or DNA chip. You can do it.
- the protein expression level measurement is performed by multiple reaction monitoring (MRM), parallel reaction monitoring (PRM), sequential windowed data independent acquisition of the total high- It can be performed using resolution (SWATH), selected reaction monitoring (SRM) or immune multiple reaction monitoring (iMRM).
- MRM multiple reaction monitoring
- PRM parallel reaction monitoring
- SWATH resolution
- SRM selected reaction monitoring
- iMRM immune multiple reaction monitoring
- the analysis in step (b) may be performed by a statistical analysis method.
- the statistical analysis method may include a linear or nonlinear regression analysis method, a linear or nonlinear classification analysis method, a logistic regression method, and an Analysis of Variance; ANOVA), neural network analysis method, genetic analysis method, support vector machine analysis method, hierarchical analysis or clustering analysis method, hierarchical algorithm using decision tree or kernel principal component analysis method, Markov Blanket analysis method , Recursive feature elimination or entropy-basic regression feature elimination analysis method, forward floating search or rear floating search analysis method, and a combination thereof.
- ANOVA Analysis of Variance
- the complex marker for diabetic retinopathy diagnosis of the present invention has superior sensitivity and diagnostic performance compared to the combination of other markers, and when the protein quantitative value of the complex marker and basic clinical information are combined and analyzed, it is highly diagnosed in early diabetic retinopathy. It was confirmed that it showed the ability.
- the composite marker of the present invention can be conveniently used for early diagnosis of diabetic retinopathy because it can be conveniently analyzed using patient plasma without using a biopsy as a blood protein.
- DMR diabetic retinopathy
- Non DMR Non-diabetic retinopathy
- FIG. 2 is data analyzed by statistically processing a logistic regression model (A) and a T-test (B) by combining quantitative protein values of complex markers and basic clinical information of patients with nonproliferative diabetic retinopathy (NPDR: nonproliferative diabetic Retinopathy
- NPDR nonproliferative diabetic Retinopathy
- DMR Nondiabetic retinopathy
- 3 is data analyzed by statistically processing a logistic regression model (A) and a T-test (B) by combining the quantitative value of protein of a complex marker and basic clinical information of a patient with proliferative diabetic retinopathy (PDR: proliferative diabetes Retinopathy Non DMR: Nondiabetic retinopathy).
- A logistic regression model
- B T-test
- FIG. 4 is data analyzed by statistically processing the protein quantification value of a complex marker and basic clinical information of a patient with staged nonproliferative diabetic retinopathy by a T-test.
- A is data comparing non-diabetic retinopathy (Non DMR) and mild nonproliferative diabetic retinopathy (mild NPDR)
- B is data comparing non-diabetic retinopathy (Non DMR) and moderate diabetic retinopathy (moderate NPDR).
- C is data comparing non-diabetic retinopathy (Non DMR) and severe diabetic retinopathy (sever NPDR).
- FIG. 5 is a protein according to a combination of MLB2, IGFBP2, LGALS3BP and PNLIP (combination 1) and ADAMTSL2, CP, DDI, FCN2, SIGLEC14, SELE, THBS1, ZG16B and CFH combination (combination 2) among the 13 markers identified in the present invention.
- This data is analyzed by statistically processing a logistic regression model by combining quantitative values and basic clinical information of all diabetic retinopathy patients.
- the present invention is a composite for diabetic retinopathy diagnosis comprising manose-binding protein C (MBL2), pancreatic triacylglycerol lipase (PNLIP), galectin-3-binding protein (LGALS3BP), and insulin like growth factor binding protein 2 (IGFBP2). It is about the marker.
- MDL2 manose-binding protein C
- PNLIP pancreatic triacylglycerol lipase
- LGALS3BP galectin-3-binding protein
- IGFBP2 insulin like growth factor binding protein 2
- diagnosis means identifying the presence or characteristics of a pathological condition. For the purposes of the present invention, the diagnosis is to determine whether diabetic retinopathy has occurred.
- diagnostic marker refers to a polypeptide or nucleic acid showing a significant increase or decrease in the gene expression level or the protein expression level in an individual with diabetic retinopathy compared to a normal control (individual non-diabetic retinopathy) ( Examples: mRNA, etc.), lipids, glycolipids, glycoproteins, and organic biomolecules such as sugars (monosaccharides, disaccharides, oligosaccharides, etc.).
- Diabetic retinopathy is classified into early nonproliferative diabetic retinopathy (NPDR) and late proliferative diabetic retinopathy (PDR) according to the degree of progression.
- Nonproliferative diabetic retinopathy is characterized by the inability to develop blood vessels.
- Proliferative diabetic retinopathy differs in its mechanism, such as blood vessel development, and nonproliferative diabetic retinopathy does not necessarily progress to proliferative diabetic retinopathy, so even a marker known as a diagnostic marker for proliferative diabetic retinopathy must be It cannot be used as a diagnostic marker for nonproliferative diabetic retinopathy.
- the composite marker of the present invention can specifically diagnose both non-proliferative diabetic retinopathy and proliferative diabetic retinopathy, and in particular, can diagnose an early stage of non-proliferative diabetic retinopathy.
- the complex marker is ADAMTSL2 (ADAMTS-like protein 2), Cp (Ceruloplasmin), CFH (complement factor H), DDI2 (Protein DDI1 homolog2), FCN2 (Ficolin 2), SELE (E-selectin), SIGLEC14 (Sialic acid-binding Ig-like lectin 14), THBS1 (Thrombospondin-1), and ZG16B (Zymogen granule protein 16 homolog B) It may be characterized in that it further comprises at least one marker selected from the group consisting of.
- ADAMTSL2 (ADAMTS-like protein 2) is a member of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-like protein subfamily, and is a glycoprotein that binds to the cell surface and extracellular matrix.
- ADAMTSL2 interacts with LTBP1 (latent transforming growth factor beta binding protein 1), and LTBP1 protein is involved in the storage of TGF- ⁇ 1, an important growth factor that regulates cell growth and division, so ADAMTSL2 has the possibility of using TGF- ⁇ 1. Adjust.
- ADAMTSL2 is expressed in cancer tissues, it is used as a marker for cancer diagnosis.
- the ADAMTSL2 may preferably include the amino acid sequence of SEQ ID NO: 1, but the amino acid sequence of SEQ ID NO: 1 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- Cp is the main protein that carries copper in the blood and plays an important role in iron metabolism. More than 95% of copper is present in the plasma of healthy people in the form of ceruloplasmin.
- the Cp may preferably include the amino acid sequence of SEQ ID NO: 2, but the amino acid sequence of SEQ ID NO: 3 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- CFH complement factor H
- complement factor H is a glycoprotein that plays an essential role in maintaining the immune response by regulating complement activation. It binds to the same sugar chain structure on the cell surface and acts as a complement inhibitor to prevent complement activation and amplification.
- the CFH may preferably include the amino acid sequence of SEQ ID NO: 3, but the amino acid sequence of SEQ ID NO: 3 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- DDI2 Protein DDI1 homolog2 is an internal peptide cleavage enzyme that activates nuclear respiratory factor 1 (Nrf1), which is involved in regulating cell growth and DNA replication, and compensates for proteasome degradation.
- Nrf1 nuclear respiratory factor 1
- the DDI2 may preferably include the amino acid sequence of SEQ ID NO: 4, but the amino acid sequence of SEQ ID NO: 4 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- FCN2 (Ficolin 2) is a type of oligolectin and is composed of a short N-terminal partial-collagen-like domain and a fibrinogen-like domain. It is mainly expressed in the liver and is known to play an important role in the lectin pathway of the complement system by binding to N-acetylglucosamin in the bacterial cell wall and acting as an opsonin like a mannose binding protein.
- the FCN2 may preferably include the amino acid sequence of SEQ ID NO: 5, but the amino acid sequence of SEQ ID NO: 5 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- IGFBP2 insulin like growth factor binding protein 2
- IGFBP2 insulin like growth factor binding protein 2
- IGFBP2 insulin like growth factor
- the IGFBP2 may preferably include the amino acid sequence of SEQ ID NO: 6, but the amino acid sequence of SEQ ID NO: 6 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- LGALS3BP (galectin-3-binding protein) is a protein encoded by the LGALS3BP gene, and specifically binds to Mac-2 (human macrophage-associated lectin) and galactin 1 (galectin 1). LGALS3BP is known to increase in serum of cancer patients and HIV-infected patients, and is involved in immune responses associated with natural killer (NK) cells and lymphokine-activated killer (LAK) cytotoxicity.
- NK natural killer
- LAK lymphokine-activated killer
- the LGALS3B may preferably include the amino acid sequence of SEQ ID NO: 7, but the amino acid sequence of SEQ ID NO: 7 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- Mannose-binding protein C is also referred to as mannose-binding lectin (MBL) or mannan-binding protein (MBP).
- MBL2 has an oligomer structure (400-700 kDa) and is composed of subunits containing three identical peptide chains consisting of approximately 30 kDa. It is produced by the liver in response to infection and is part of a number of other factors called acute stage proteins.
- the MBL2 may preferably include the amino acid sequence of SEQ ID NO: 8, but the amino acid sequence of SEQ ID NO: 8 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- PNLIP pancreatic triacylglycerol lipase
- PNLIP pancreatic triacylglycerol lipase
- PNLIP is known to have a low serum concentration because it is secreted into the duodenum through the pancreatic duct system.However, when pancreatic functions such as pancreatitis or pancreatic adenocarcinoma are extremely destroyed, pancreatic enzymes including PNLIP are secreted into the serum. It is known that acute pancreatitis can be diagnosed by measuring.
- the PNLIP may preferably include the amino acid sequence of SEQ ID NO: 9, but the amino acid sequence of SEQ ID NO: 9 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- SELE E-selectin
- CD62E CD62 antigen-like family member E
- ELAM-1 endothelial-leukocyte adhesion molecule 1
- LECAM2 leukocyte-endothelial cell adhesion molecule 2
- interleukin 1 ⁇ tumor necrosis factor.
- SELE is a cell adhesion molecule that is transiently expressed and induced in vascular endothelial cells activated by lipopolysaccharides with a peak of 4 to 12 hours.
- SELE is strongly expressed in vascular endothelial cells in inflammatory tissues and promotes invasion of these cells into the inflammatory site by mediating the phenomenon that neutrophils and monocytes roll over vascular endothelial cells. It is known to be involved in adhesion of cancer cells to vascular endothelial cells.
- the SELE may preferably include the amino acid sequence of SEQ ID NO: 10, but the amino acid sequence of SEQ ID NO: 10 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- SIGLEC14 (Sialic acid-binding Ig-like lectin 14) is one of the subfamily of SIGLEC (Sialic acid-binding immunoglobulin-type lectins), and SIGLEC is a cell surface protein that binds to sialic acid and is mainly expressed on the surface of immune cells.
- the protein interaction between SIGLEC and sialic acid acts as a switch to turn on and off the immune system, and cancer cells are also known to acquire resistance to the immune response by using the SIGLEC-sialic acid reaction.
- the SIGLEC14 may preferably include the amino acid sequence of SEQ ID NO: 11, but the amino acid sequence of SEQ ID NO: 11 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- THBS1 Thrombospondin-1
- thrombospondin-1 is one of the thrombospondin family and is a glycoprotein that inhibits neovascularization and tumorigenesis. It is known that it binds to proteases related to angiogenesis, such as plasminogen, urokinase, MMP, thrombin, and cathepsin, and regulates adhesion, migration, and growth of endothelial cells.
- the THBS1 may preferably include the amino acid sequence of SEQ ID NO: 12, but the amino acid sequence of SEQ ID NO: 12 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- ZG16B (Zymogen granule protein 16 homolog B) is a pancreatic adenocarcinoma upregulated factor (PAUF), and is known to bind to carbohydrates and activate internal epithelial cells, angiogenesis, and permeability.
- PAUF pancreatic adenocarcinoma upregulated factor
- the ZG16B may preferably include the amino acid sequence of SEQ ID NO: 13, but the amino acid sequence of SEQ ID NO: 13 and 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98 % Or more, or 99% or more of the same sequence may be included.
- the markers can be used for diabetic retinopathy, and in particular, it is possible to increase the diagnostic performance of diabetic retinopathy by using a complex marker of MBL2, PNLIP, LGALS3BP and IGFBP2. None is known about the disclosed technology.
- the present invention is a complex for diabetic retinopathy diagnosis including manose-binding protein C (MBL2), pancreatic triacylglycerol lipase (PNLIP), galectin-3-binding protein (LGALS3BP), and insulin like growth factor binding protein 2 (IGFBP2). It relates to a composition for diabetic retinopathy diagnosis comprising an agent measuring the level of mRNA or protein of a marker.
- MBL2 manose-binding protein C
- PNLIP pancreatic triacylglycerol lipase
- LGALS3BP galectin-3-binding protein
- IGFBP2 insulin like growth factor binding protein 2
- ADAMTSL2 ADAMTS-like protein 2
- Cp Ceruloplasmin
- CFH complement factor H
- DDI2 Protein DDI1 homolog2
- FCN2 Ficolin 2
- SELE E-selectin
- SIGLEC14 Sialic acid-binding Ig) -like lectin 14
- THBS1 Thrombospondin-1
- ZG16B Zymogen granule protein 16 homolog B
- ZG16B Zymogen granule protein 16 homolog B
- the agent for measuring the mRNA level of the complex marker is characterized in that it is a primer pair, probe or antisense nucleotide that specifically binds to the gene of the marker, and nucleic acid information of the genes is known in GeneBank, etc. Can design these primer pairs, probes or antisense nucleotides based on the above sequence.
- the term "measurement of mRNA expression level" as used in the present invention is a process of confirming the presence and expression of mRNA of diabetic retinopathy diagnosis genes in a biological sample isolated from a patient suspected of diabetic retinopathy to diagnose diabetic retinopathy. Measure the amount.
- primer as used in the present invention is a fragment that recognizes a target gene sequence, and includes forward and reverse primer pairs, preferably, a primer pair that provides an analysis result having specificity and sensitivity.
- a primer that amplifies only the target gene sequence containing the complementary primer binding site and does not induce non-specific amplification can give high specificity. .
- probe used in the present invention refers to a substance capable of specifically binding to a target substance to be detected in a sample, and refers to a substance capable of specifically confirming the presence of a target substance in a sample through the binding. do.
- the type of probe is a material commonly used in the art and is not limited, but preferably PNA (peptide nucleic acid), LNA (locked nucleic acid), peptide, polypeptide, protein, RNA or DNA, and most preferred Hagi is PNA.
- the probe is a biomaterial that includes an organism-derived or similar thing or a thing produced in vitro, for example, enzymes, proteins, antibodies, microorganisms, animal and plant cells and organs, neurons, DNA, and It may be RNA, DNA includes cDNA, genomic DNA, oligonucleotide, RNA includes genomic RNA, mRNA, oligonucleotide, and examples of proteins include antibodies, antigens, enzymes, peptides, and the like.
- antisense refers to a nucleotide base in which an antisense oligomer is hybridized with a target sequence in RNA by Watson-Crick base pairing, typically allowing the formation of an mRNA and RNA: oligomeric heterodimer within the target sequence. It means an oligomer having a sequence of and a backbone between subunits. Oligomers may have exact sequence complementarity or approximate complementarity to the target sequence.
- the agent for measuring the protein level of the complex marker is an antibody, interacting protein, ligand, nanoparticles, or aptamer that specifically binds to the protein or peptide fragment. can do.
- protein expression level measurement is a process of checking the presence and expression of a protein expressed from a diabetic retinopathy diagnosis gene in a biological sample in order to diagnose diabetic retinopathy.
- an antibody refers to a substance that specifically binds to an antigen and causes an antigen-antibody reaction.
- an antibody refers to an antibody that specifically binds to the complex biomarker for diabetic retinopathy of the present invention.
- the antibodies of the present invention include polyclonal antibodies, monoclonal antibodies and recombinant antibodies.
- the antibody can be easily prepared using techniques well known in the art.
- the polyclonal antibody can be produced by a method well known in the art, including the process of injecting the diabetic retinopathy marker protein antigen into an animal and collecting blood from the animal to obtain serum containing the antibody.
- Such polyclonal antibodies can be prepared from any animal such as goat, rabbit, sheep, monkey, horse, pig, cow, dog.
- the monoclonal antibody is a hybridoma method well known in the art (see the hybridoma method; Kohler and Milstein, European Journal of Immunology 6:511-519, 1976), or phage antibody library technology (Clackson et al, Nature, 352 :624-628, 1991; Marks et al, J. Mol . Biol. , 222:58, 1-597, 1991).
- the antibody prepared by the above method may be separated and purified using a method such as gel electrophoresis, dialysis, salt precipitation, ion exchange chromatography, and affinity chromatography.
- the antibody of the present invention includes a complete form having two full-length light chains and two full-length heavy chains, as well as functional fragments of antibody molecules.
- the functional fragment of an antibody molecule means a fragment that has at least an antigen-binding function, and includes Fab, F(ab'), F(ab') 2 and Fv.
- the antibody of the present invention may be obtained commercially.
- PNA Protein Nucleic Acid
- DNA has a phosphate-ribose sugar backbone
- PNA has a repeated N-(2-aminoethyl)-glycine backbone linked by a peptide bond, which greatly increases the binding power and stability to DNA or RNA, resulting in molecular biology. , Diagnostic analysis and antisense therapy. PNA is described in detail in Nielsen PE et al, Science , 254(5037):1497-500, 1991.
- aptamer is an oligonucleotide or peptide molecule, and general information of the aptamer is described in Bock LC et al. , Nature , 355(6360):5646, 1992; Hoppe-Seyler F and Butz K, J Mol Med ., 78(8):42630, 2000; Cohen BA et al. , Proc Natl Acad Sci USA ., 95(24):142727, 1998).
- the present invention relates to a diabetic retinopathy diagnosis kit comprising the diabetic retinopathy diagnosis composition.
- the kit can be prepared by a conventional manufacturing method known in the art.
- the kit may include, for example, an antibody in a freeze-dried form, a buffer, a stabilizer, an inactive protein, and the like.
- the kit may further include a detectable label.
- detectable label refers to an atom or molecule that specifically detects a molecule containing a label among molecules of the same type without a label.
- the detectable label may be attached to an antibody, interacting protein, ligand, nanoparticle, or aptamer that specifically binds to the protein or fragment thereof.
- the detectable label may include a radionuclide, a fluorophore, or an enzyme.
- the kit can be used according to various immunoassays or immunostaining methods known in the art.
- the immunoassay or immunostaining method may include radioimmunoassay, radioimmunoprecipitation, immunoprecipitation, ELISA, capture-ELISA, inhibition or competition analysis, sandwich analysis, flow cytometry, immunofluorescence staining, and immunoaffinity purification.
- the kit may be a reverse transcription polymerase chain reaction (RT-PCR) kit, a DNA chip kit, an enzyme linked immunosorbent assay (ELISA) kit, a protein chip kit, a rapid kit, or a multiple reaction monitoring (MRM) kit.
- RT-PCR reverse transcription polymerase chain reaction
- ELISA enzyme linked immunosorbent assay
- MRM multiple reaction monitoring
- the kit can be used for mass spectrometry.
- the specific amino acid residues of the protein are myristoylation, isoprenylation, prenylation, glypiation, lipoylation, acylation, alkylation, methylation, demethylation, amidation, It may have modifications such as ubiquitination, phosphorylation, deamidation, glycosylation, oxidation, or acetylation.
- the present invention provides, from a biological sample of a patient (a) MBL2 (mannose-binding protein C), PNLIP (pancreatic triacylglycerol lipase), LGALS3BP (galectin-3-binding protein), and IGFBP2 (insulin like growth factor binding protein). Measuring the mRNA or protein level of the complex marker for diabetic retinopathy diagnosis consisting of 2); And
- It relates to a method for providing information for diabetic retinopathy diagnosis comprising; (b) comparing the mRNA or protein expression level with a control sample.
- the complex marker in step (a) is ADAMTSL2 (ADAMTS-like protein 2), Cp (Ceruloplasmin), CFH (complement factor H), DDI2 (Protein DDI1 homolog2), FCN2 (Ficolin 2), SELE ( E-selectin), SIGLEC14 (Sialic acid-binding Ig-like lectin 14), THBS1 (Thrombospondin-1), and ZG16B (Zymogen granule protein 16 homolog B), characterized by further comprising at least one marker selected from the group consisting of To do.
- ADAMTSL2 ADAMTS-like protein 2
- Cp Ceruloplasmin
- CFH complement factor H
- DDI2 Protein DDI1 homolog2
- FCN2 Fecolin 2
- SELE E-selectin
- SIGLEC14 Sialic acid-binding Ig-like lectin 14
- THBS1 Thrombospondin-1
- biological sample refers to a sample such as tissue, cells, blood, serum, plasma, saliva, cerebrospinal fluid or urine, in which the protein expression level or gene expression level differs due to the onset of diabetic retinopathy. And, preferably, it means blood, plasma, and serum.
- the method of providing information for diabetic retinopathy is at least one selected from the group consisting of patient's age, body mass index (BMI), Hb1Ac test result, insulin treatment, smoking, high blood pressure, hyperlipidemia, and cardiovascular disease. Additional clinical information may be included.
- the method of providing information for diagnosing diabetic retinopathy may further include determining that it is diabetic retinopathy if the gene expression level or protein expression level of the complex marker increases compared to the control group.
- the mRNA expression level in step (a) can be measured and compared using a primer pair, a probe, or an antisense nucleotide specifically binding to the gene of the complex marker.
- mRNA expression level measurement or comparative analysis method reverse transcriptase polymerase reaction, competitive reverse transcriptase polymerase reaction, real-time reverse transcriptase polymerase reaction, RNase protection assay, Northern blotting or DNA chip, etc. can be used, but the present invention It is not limited to these.
- the mRNA expression level in the normal control group and the mRNA expression level in diabetic retinopathy patients can be checked, and the onset of diabetic retinopathy can be diagnosed or predicted by comparing the levels of these expression levels.
- the measurement of the protein expression level in step (a) may be measured and compared using antibodies, interacting proteins, ligands, nanoparticles, or aptamers that specifically bind to proteins or peptide fragments.
- Protein expression level measurement or comparative analysis methods include protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption/Ionization Time of Flight Mass Spectrometry) analysis, SELDITOF (Sulface Enhanced Laser Desorption/Ionization Time of Flight).
- MALDI-TOF Microx Desorption/Ionization Time of Flight Mass Spectrometry
- SELDITOF Surface Enhanced Laser Desorption/Ionization Time of Flight
- Mass Spectrometry Analysis Radiation Immunoassay, Radioimmune Diffusion Method, Okteroni Immunity Diffusion Method, Rocket Immunoelectrophoresis, Tissue Immunostaining, Complement Fixation Analysis, 2D Electrophoresis Analysis, Liquid Chromatography-Mass Spectrometry, LC-MS), LCMS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blot, and ELISA (enzyme linked immunosorbentassay), but are not limited thereto.
- MRM multiple reaction monitoring
- PRM parallel reaction monitoring
- SWATH sequential windowed data independent acquisition of the total high-resolution
- SRM selected reaction monitoring
- iMRM immune multiple reaction monitoring
- the MRM is a method of determining an exact fragment of a material, breaking it in a mass spectrometer, selecting a specific ion from the broken ions once more, and obtaining the number using a continuously connected detector.
- the protein or fragment thereof can be quantified using a mass spectrometer in blood samples of normal individuals and individuals suspected of diabetic retinopathy.
- the analysis in step (b) can be analyzed using a statistical method or an algorithm to improve the accuracy of the diagnosis, and a linear or nonlinear regression analysis method, an preceding or nonlinear classification analysis method, and a logistic regression analysis method (logistic regression), Analysis of Variance (ANOVA), neural network analysis method, genetic analysis method, support vector machine analysis method, hierarchical analysis or clustering analysis method, hierarchical algorithm or kernel principal component analysis using decision trees Method, Markov Blanket analysis method, recursive feature elimination or entropy-basic regression feature elimination analysis method, forward floating search or rear floating search analysis method, and their An analysis method selected from the group consisting of combinations can be used.
- the statistical method uses a logistic regression analysis method, but is not limited thereto.
- 155 plasma samples were analyzed for tactical verification of biomarkers for diabetic retinopathy among plasma proteins (Table 1), IGFBP2 (insulin like growth factor binding protein 2), ADAMTSL2 ( ADAMTS-like protein 2), CFH (Complement factor H), Cp (Ceruloplasmin), DDI2 (Protein DDI1 homolog2), FCN2 (Ficolin 2), LGALS3BP (galectin 3 binding protein), MBL2 (mannose-binding protein C), PNLIP 13 markers consisting of (pancreatic triacylglycerol lipase), SELE (E-selectin), SIGLEC14 (Sialic acid-binding Ig-like lectin 14), THBS1 (Thrombospodin-1) and ZG16B (Zymogen granule protein 16 homolog B) It was analyzed using multiple reaction monitoring (MRM). As shown in Table 2, for quantitative analysis, peptides for each marker were selected and
- the biomarker expression level conversion information and the clinical information conversion level are input using a logistic regression model to confirm the diagnostic ability improvement effect.
- the probability of classification as diabetic retinopathy was estimated.
- Table 3 based on clinical information + MBL2 + PNLIP + LGALS3BP + IGFBP2, the expression levels for ADAMTSL2, Cp, DDI2, FCN2, SELE, SIGLEC14, THBS1, ZG16B and CFH were added and analyzed one by one. It was confirmed that the diagnostic ability of diabetic retinopathy increased as the number of markers increased.
- Example 1 Diabetic retinopathy patient selection and plasma collection
- Plasma samples from diabetic retinopathy patients were collected with the approval of the Institutional Review Board of Seoul National University Bundang Hospital. A total of 155 plasma samples were analyzed for quantitative detection of biomarkers using plasma proteins, and the clinical characteristics of the analyzed normal group (Non DMR) and diabetic retinopathy (DMR) disease group are shown in Table 1 below.
- IGFBP2 insulin like growth factor binding protein 2
- ADAMTSL2 ADAMTS-like protein 2
- CFH Complement factor H
- Cp Ceruloplasmin
- DDI2 Protein DDI1 homolog2
- FCN2 Fecolin 2
- LGALS3BP galectin 3 binding protein
- MBL2 mannose-binding protein C
- PNLIP pancreatic triacylglycerol lipase
- SELE E-selectin
- SIGLEC14 Sialic acid-binding Ig-like lectin 14
- THBS1 Thrombospodin-1)
- ZG16B Zymogen granule protein 16 homolog B
- a representative peptide having a specific charge-to-mass ratio (m/z) for 13 biomarker proteins is selected (Q1), and the peptide is broken by electric shock.
- the ion (Q3) having the highest intensity was selected.
- At least one peptide with high sensitivity per protein was measured and injected into a mass spectrometer based on this to obtain an optimum value of fragmentation energy per transition, and three or more upper fragmented ions were selected based on the intensity (Table 2).
- SIS Stable-isotope labeled standard
- SIS peptide is a peptide obtained by substituting 13C and 15N for 12C and 14N in the amino acids of lysine (Lys, K) or arginine (Arg, R) at the C-terminus of the peptide. This has a difference in mass value from the endogenous peptide present in the blood, but since it has the same sequence, the peptide hydrophobicity is the same, so it elutes at the same retention time (RT) on the chromatogram.
- RT retention time
- Example 1 Each plasma obtained in Example 1 was used as it is, or 14 kinds of proteins (Albumin, IgG, Antitrypsin, IgA, Transferrin, Haptoglobin, Fibrinogen, Alpha2-Macroglobulin, etc.) exist in high amounts for more accurate protein quantification.
- Alpha1-Acid glycoprotein, IgM, Apolipoprotein AI, Apolipoprotein AII, Complement C3, Transthyretin) were removed.
- 14 kinds of proteins were removed using a MARS (Multiple affinity removal system, Agilent, USA) column according to the manufacturer's method, and the remaining proteins were eluted and used for analysis.
- MARS Multiple affinity removal system
- 2-carboxylethyltrisphosphine Tris(2-carboxyethyl)-phosphine, TECP
- 2-chloro 2-chloroacetamide
- Acetamide (2-chloroacetamide) was added and reacted at 25° C. for 1 hour to reduce and alkylate disulfide bonds.
- Rice seed enzyme was added so that the mass ratio of plasma protein to rice seed (wako) enzyme was 100:1, and reacted at room temperature for 4 hours.
- Example 2-1 a heavy-labeled peptide was added (spiking) as an internal standard material (SIS peptide) determined in Example 2-1 to perform MRM analysis.
- SIS peptide an internal standard material
- Nano ultra 2D plus (Eksigent), a triple quadrupole mass spectrometer, QTarp 5500 (SCIEX) was used to monitor the transition of each selected protein in a scheduled MRM mode.
- the peak area of the transition was calculated by processing raw data using Skyline (Mccoss lab, University of Washington, USA). Relative concentrations were compared for the endogenous/heavy labeled peptide using the peak area. Using the measured results, T-test and AUROC (Area under the receiver operating characteristic) values were generated to measure the predictive ability of each protein peptide. To confirm the predictive power combined with clinical information, the expression level conversion information and the clinical information conversion level in Table 1 were input using a logistic regression model to estimate a probability value classified as diabetic retinopathy. All statistical analyzes were performed using MedCal ver 17.1 (MedCalc).
- the clinical information reflected the body mass index (BMI), smoking, hyperlipidemia, hypertension, cardiovascular disease, and glycated hemoglobin (Hb1Ac) calculated by the height and weight obtained through the interview.
- BMI body mass index
- Hb1Ac glycated hemoglobin
- Example 3 composite bio Marker group According to the combination of results and clinical information Diagnostic ability Check for improvement
- a logistic regression model is used to input biomarker expression level conversion information and clinical information conversion level to confirm the diagnostic effect.
- the probability values to be classified were estimated.
- Diabetic retinopathy diagnosis performance according to the number of combined biomarkers C1 (combination 1) C2 C3 C4 C5 C6 C7 C8 C9 C10 AUC One 2 3 4 5 0.784 One 2 3 4 5 6 0.803 One 2 3 4 5 6 7 0.804 One 2 3 4 5 6 7 8 0.812 One 2 3 4 5 6 7 8 9 0.814 One 2 3 4 5 6 7 8 9 10 0.819 One 2 3 4 5 6 7 8 9 10 11 0.823 One 2 3 4 5 6 7 8 9 10 11 12 0.824 One 2 3 4 5 6 7 8 9 10 11 12 13 0.834 One 2 3 4 5 6 7 8 9 10 11 12 13 14 0.863
- C Clinical information
- P Protein quantitative information
- Com Clinical and protein quantitative information included
- AUC Area Under the Curve
- SE Standard Error (Delong et al. , 1988)
- 95% CI 95% confidence interval ( Confidence Interval)
- the complex marker for diagnosing diabetic retinopathy not only has superior sensitivity and diagnostic performance compared to combinations of other markers, but also has a high diagnosis in early diabetic retinopathy by combining the quantitative value of protein and basic clinical information of the complex marker. As it shows the ability, it can be usefully used for early diagnosis of diabetic retinopathy.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
시료(n=155) | ||||||
Non DMR(n=36) | DMR(n=119) | NPDR(n=60) | PDR(n=59) | |||
Mild(n=17) | Moderate(n=17) | Severe(n=26) | ||||
나이 | 64.1±8.3 | 57.5±9.5 | 57.4±10.9 | 58.9±12.1 | 60.0±7.6 | 56.1±9.0 |
성별(여/남) | 29/7 | 29/90 | 12/5 | 3/14 | 5/21 | 9/50 |
Hb1Ac | 7.4±1.3 | 7.6±1.4 | 7.5±0.9 | 7.6±1.4 | 7.5±1.4 | 7.6±1.5 |
당뇨치료(%) | 32(88.9) | 116(97.5) | 17(100.0) | 17(100.0) | 25(96.2) | 57(96.6) |
Systemic risk factor | ||||||
BMI(%) | ||||||
저 | 4(11.1) | 7(5.9) | 0(0) | 1(5.9) | 3(11.5) | 3(5.1) |
정상 | 19(52.8) | 64(53.8) | 8(47.1) | 8(47.1) | 13(50.0) | 35(59.3) |
경도 | 12(33.3) | 37(31.1) | 8(47.1) | 4(23.5) | 9(34.6) | 15(25.4) |
고도 | 1(2.8) | 11(9.2) | 1(5.9) | 4(23.5) | 0(0) | 6(10.2) |
흡연(%) | 12(33.3) | 53(43.7) | 10(58.5) | 8(47.1) | 10(38.5) | 24(40.7) |
고혈압(%) | 19(52.8) | 65(54.6) | 6(35.3) | 10(58.8) | 14(53.8) | 35(59.3) |
고지혈증(%) | 25(69.4) | 50(42.0) | 9(52.9) | 8(47.1) | 10(38.5) | 23(39.0) |
심혈관질환(%) | 5(13.9) | 9(7.6) | 1(5.9) | 1(5.9) | 2(7.7) | 5(8.5) |
유전자명 | 트립신절편 | 서열번호 | 표적이온 | 표적 m/z |
ADAMTSL2 | NFNIAGTVVK | 서열번호 14 | +2y6 | 531.801/574.356 |
Cp | GEFYIGSK | 서열번호 15 | +2y6 | 450.728/714.382 |
AEVGDTI | 서열번호 16 | +2y5 | 430.727/561.299 | |
CFH | SLGNIIMVCR | 서열번호 17 | +2y5 | 581.807/678.343 |
SLGNVIMVCR | 서열번호 18 | +2y5 | 574.799/678.343 | |
CYFPYLENGYNQNYGR | 서열번호 19 | +2y14+2 | 1029.444/867.897 | |
CYFPYLENGYNQNHGR | 서열번호 20 | +3y13+2 | 677.964/781.361 | |
DDI2 | DGDVVILR | 서열번호 21 | +2y4 | 443.753/500.355 |
IDFSSIAVPGTSSPR | 서열번호 22 | +2y7 | 767.399/701.358 | |
FCN2 | LQAADTCPEVK | 서열번호 23 | +2y8 | 616.303/919.419 |
IGFBP2 | LIQGAPTIR | 서열번호 24 | +2y6 | 484.798/614.362 |
LGALS3BP | SDLAVPSELALLK | 서열번호 25 | +2y8 | 678.393/870.529 |
MBL2 | WLTFSLGK | 서열번호 26 | +2y6 | 476.269/652.366 |
PNLIP | TGYTQASQNIR | 서열번호 27 | +2y6 | 619.81/688.374 |
GEENWLANVCK | 서열번호 28 | +2y5 | 660.306/591.292 | |
VTGHILVSLFGNK | 서열번호 29 | +3y4 | 462.270/465.246 | |
SELE | NWAPGEPNNR | 서열번호 30 | +2y7 | 577.771/783.374 |
QPQNGSVR | 서열번호 31 | +2y6 | 443.230/660.342 | |
SIGLEC14 | EGGEFTCR | 서열번호 32 | +2y3 | 478.201/436.197 |
THBS1 | GGVNDNFQGVLQNVR | 서열번호 33 | +2y7 | 808.911/785.463 |
ZG16B | YFSTTEDYDHEITGLR | 서열번호 34 | +3y7 | 649.63/825.458 |
C1 (조합1) | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 | C10 | AUC | ||||
1 | 2 | 3 | 4 | 5 | 0.784 | |||||||||
1 | 2 | 3 | 4 | 5 | 6 | 0.803 | ||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 0.804 | |||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 0.812 | ||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 0.814 | |||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 0.819 | ||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 0.823 | |||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 0.824 | ||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 0.834 | |
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 0.863 |
Non DMR vs DMR (STAGE 1) | Non DMR vs NPDR (STAGE 2) | Non DMR vs PDR(STAGE 3) | |||||||
AUC | SE | 95% CI | AUC | SE | 95% CI | AUC | SE | 95% CI | |
C | 0.628 | 0.0550 | 0.520 ~ 0.735 | 0.644 | 0.0611 | 0.524 ~0.764 | 0.611 | 0.0602 | 0.493 ~0.729 |
P | 0.813 | 0.0368 | 0.741 ~ 0.886 | 0.814 | 0.0434 | 0.729 ~0.900 | 0.813 | 0.0439 | 0.727 ~0.899 |
Com | 0.863 | 0.0342 | 0.796 ~ 0.930 | 0.848 | 0.0401 | 0.769 ~ 0.927 | 0.879 | 0.0362 | 0.808 ~0.949 |
Claims (11)
- MBL2(mannose-binding protein C), PNLIP(pancreatic triacylglycerol lipase), LGALS3BP(galectin-3-binding protein) 및 IGFBP2(insulin like growth factor binding protein 2)을 포함하는, 당뇨망막병증 진단용 복합 마커.
- 제1항에 있어서, 상기 복합 마커는 ADAMTSL2(ADAMTS-like protein 2), Cp(Ceruloplasmin), CFH(complement factor H), DDI2(Protein DDI1 homolog2), FCN2(Ficolin 2), SELE(E-selectin), SIGLEC14(Sialic acid-binding Ig-like lectin 14), THBS1(Thrombospondin-1) 및 ZG16B(Zymogen granule protein 16 homolog B)로 구성된 군에서 선택된 1종 이상의 마커를 추가로 포함하는 것을 특징으로 하는, 당뇨망막병증 진단용 복합 마커.
- MBL2(mannose-binding protein C), PNLIP(pancreatic triacylglycerol lipase), LGALS3BP(galectin-3-binding protein) 및 IGFBP2(insulin like growth factor binding protein 2)을 포함하는 당뇨망막병증 진단용 복합 마커의 mRNA 또는 단백질 수준을 측정하는 제제를 포함하는, 당뇨망막병증 진단용 조성물.
- 제3항에 있어서, 상기 조성물은 ADAMTSL2(ADAMTS-like protein 2), Cp(Ceruloplasmin), CFH(complement factor H), DDI2(Protein DDI1 homolog2), FCN2(Ficolin 2), SELE(E-selectin), SIGLEC14(Sialic acid-binding Ig-like lectin 14), THBS1(Thrombospondin-1) 및 ZG16B(Zymogen granule protein 16 homolog B)로 구성된 군에서 선택된 1종 이상의 마커에 대한 mRNA 또는 단백질 수준을 측정하는 제제를 추가로 포함하는 것을 특징으로 하는, 당뇨망막병증 진단용 조성물.
- 제3항에 있어서, 상기 복합 마커의 mRNA 수준을 측정하는 제제는 상기 마커의 유전자에 특이적으로 결합하는 프라이머쌍, 프로브 또는 안티센스 뉴클레오타이드인 것을 특징으로 하는, 당뇨망막병증 진단용 조성물.
- 제3항에 있어서, 상기 복합 마커의 단백질 수준을 측정하는 제제는 상기 마커의 단백질 또는 펩타이드 단편에 특이적으로 결합하는 항체, 상호작용 단백질, 리간드, 나노입자(nanoparticles) 또는 압타머(aptamer)인 것을 특징으로 하는, 당뇨망막병증 진단용 조성물.
- 제3항 내지 제6항 중 어느 한 항의 당뇨망막병증 진단용 조성물을 포함하는, 당뇨망막병증 진단용 키트.
- 제7항에 있어서, 상기 키트는 RT-PCR(Reverse transcription polymerase chain reaction) 키트, DNA 칩 키트, ELISA(Enzymelinked immunosorbent assay) 키트, 단백질 칩 키트, 래피드(rapid) 키트 또는 MRM(Multiple reaction monitoring) 키트인 것을 특징으로 하는, 당뇨망막병증 진단용 키트.
- (a) 환자의 생물학적 시료로부터 제1항 또는 제2항의 당뇨망막병증 진단용 복합 마커의 mRNA 또는 단백질 수준을 측정하는 단계; 및(b) 상기 mRNA 또는 단백질 발현 수준을 대조군 시료와 비교하는 단계;를 포함하는, 당뇨망막병증 진단을 위한 정보제공 방법.
- 제9항에 있어서, 상기 당뇨망막병증 진단을 위한 정보제공 방법은 환자의 나이, BMI(body mass index), 흡연 여부, Hb1Ac 검사결과, 인슐린 치료 여부, 고혈압 여부, 고지혈증 여부 및 심혈관 질환 여부로 구성된 군에서 선택된 1종 이상의 임상정보를 추가로 포함하여 대조군과 비교하는 것을 특징으로 하는, 당뇨망막병증 진단을 위한 정보제공 방법.
- 제9항에 있어서, 상기 당뇨망막병증 진단을 위한 정보제공 방법은 (c) 복합 마커의 유전자 발현 수준 또는 단백질 발현 수준이 대조군에 비해 증가하면 당뇨망막병증이라고 판정하는 단계를 추가로 포함하는 것을 특징으로 하는, 당뇨망막병증 진단을 위한 정보제공 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080019161.9A CN113544513A (zh) | 2019-03-07 | 2020-03-06 | 用于诊断糖尿病视网膜病变的复合生物标志物及其用途 |
EP20767270.0A EP3955001A4 (en) | 2019-03-07 | 2020-03-06 | COMPOSITE MARKER FOR THE DIAGNOSIS OF DIABETIC RETINOPATHY AND USE THEREOF |
AU2020232805A AU2020232805B2 (en) | 2019-03-07 | 2020-03-06 | Composite marker for diagnosis of diabetic retinopathy and use thereof |
JP2021553338A JP7224690B2 (ja) | 2019-03-07 | 2020-03-06 | 糖尿病網膜症の診断用複合マーカーおよびその用途 |
US17/436,582 US20220146531A1 (en) | 2019-03-07 | 2020-03-06 | A combination of biomarkers for diagnosing of diabetic retinopathy and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190026302 | 2019-03-07 | ||
KR10-2019-0026302 | 2019-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020180146A1 true WO2020180146A1 (ko) | 2020-09-10 |
Family
ID=72337119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/003168 WO2020180146A1 (ko) | 2019-03-07 | 2020-03-06 | 당뇨망막병증 진단용 복합 마커 및 이의 용도 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220146531A1 (ko) |
EP (1) | EP3955001A4 (ko) |
JP (1) | JP7224690B2 (ko) |
KR (1) | KR102309635B1 (ko) |
CN (1) | CN113544513A (ko) |
AU (1) | AU2020232805B2 (ko) |
WO (1) | WO2020180146A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113667741A (zh) * | 2021-08-30 | 2021-11-19 | 上海市第一人民医院 | 基于trim46基因的糖尿病视网膜病检测试剂盒 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116068063A (zh) * | 2021-10-29 | 2023-05-05 | 上海市第一人民医院 | 糖尿病视网膜病变眼底硬性渗出相关的血清脂质标志物及其应用 |
CN116721760B (zh) * | 2023-06-12 | 2024-04-26 | 东北林业大学 | 融合生物标志物的多任务糖尿病性视网膜病变检测算法 |
CN117783533A (zh) * | 2023-08-08 | 2024-03-29 | 江苏省人民医院(南京医科大学第一附属医院) | 血液生物学标志物作为尿毒症钙化防御病诊断和疗效检测标志物的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1865071A1 (en) * | 2006-06-09 | 2007-12-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Method for early diagnosis of proliferative diabetic retinopathy |
KR20090012503A (ko) * | 2007-07-30 | 2009-02-04 | 주식회사 씨티씨바이오 | 당뇨병성 망막증 진단용 마커, 조성물 및 키트 |
KR20090022291A (ko) * | 2007-08-30 | 2009-03-04 | 서울대학교산학협력단 | 당뇨병성 망막병증 검출용 바이오 마커 조성물 및 진단키트 |
KR20110033484A (ko) * | 2009-09-25 | 2011-03-31 | 경북대학교 산학협력단 | 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법 |
KR20130009204A (ko) * | 2011-07-14 | 2013-01-23 | 서울대학교산학협력단 | 당뇨망막병증 진단용 마커 및 이의 용도 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080033053A1 (en) * | 2004-07-22 | 2008-02-07 | Wolfgang Curt D | Cross-Reference To Related Applications |
US20080193414A1 (en) * | 2005-05-06 | 2008-08-14 | Amanda Proudfoot | Use of an Immunoglobulin Domain-Containing Cell Surface Recognition Molecule For Treating Diseases |
US20110030072A1 (en) * | 2008-12-04 | 2011-02-03 | Sigma-Aldrich Co. | Genome editing of immunodeficiency genes in animals |
US20120177660A1 (en) * | 2011-01-06 | 2012-07-12 | Georgia Health Sciences University Research Institute, Inc. | Biomarkers and therapeutic targets for type 1 diabetes |
EP3286318A2 (en) * | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna compositions and methods of use |
WO2017086703A1 (ko) * | 2015-11-16 | 2017-05-26 | (주)레티마크 | 나이관련 황반변성 또는 당뇨망막병증 진단용 바이오마커 및 이를 이용한 진단 방법 |
KR102475301B1 (ko) * | 2016-04-08 | 2022-12-09 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
-
2020
- 2020-03-06 WO PCT/KR2020/003168 patent/WO2020180146A1/ko unknown
- 2020-03-06 AU AU2020232805A patent/AU2020232805B2/en active Active
- 2020-03-06 US US17/436,582 patent/US20220146531A1/en active Pending
- 2020-03-06 JP JP2021553338A patent/JP7224690B2/ja active Active
- 2020-03-06 EP EP20767270.0A patent/EP3955001A4/en active Pending
- 2020-03-06 KR KR1020200028365A patent/KR102309635B1/ko active IP Right Grant
- 2020-03-06 CN CN202080019161.9A patent/CN113544513A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1865071A1 (en) * | 2006-06-09 | 2007-12-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Method for early diagnosis of proliferative diabetic retinopathy |
KR20090012503A (ko) * | 2007-07-30 | 2009-02-04 | 주식회사 씨티씨바이오 | 당뇨병성 망막증 진단용 마커, 조성물 및 키트 |
KR20090022291A (ko) * | 2007-08-30 | 2009-03-04 | 서울대학교산학협력단 | 당뇨병성 망막병증 검출용 바이오 마커 조성물 및 진단키트 |
KR20110033484A (ko) * | 2009-09-25 | 2011-03-31 | 경북대학교 산학협력단 | 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법 |
KR20130009204A (ko) * | 2011-07-14 | 2013-01-23 | 서울대학교산학협력단 | 당뇨망막병증 진단용 마커 및 이의 용도 |
Non-Patent Citations (9)
Title |
---|
BOCK LC ET AL., NATURE, vol. 355, no. 6360, 1992, pages 5646 |
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
COHEN BA ET AL., PROC NATL ACAD SCI USA., vol. 95, no. 24, 1998, pages 142727 |
HOPPE-SEYLER FBUTZ K, JMOL MED., vol. 78, no. 8, 2000, pages 42630 |
KOHLERMILSTEIN, EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 6, 1976, pages 511 - 519 |
MARKS ET AL., J. MOL. BIOL., vol. 222, no. 58, 1991, pages 1 - 597 |
NIELSEN PE ET AL., SCIENCE, vol. 254, no. 5037, 1991, pages 1497 - 500 |
PUSPARAJAH, P. ET AL.: "Molecular markers of diabetic retinopathy: potential screening tool of the future?", FRONTIERS IN PHYSIOLOGY, vol. 7, 1 June 2016 (2016-06-01), pages 200, XP055736468, DOI: 10.3389/fphys.2016.00200 * |
See also references of EP3955001A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113667741A (zh) * | 2021-08-30 | 2021-11-19 | 上海市第一人民医院 | 基于trim46基因的糖尿病视网膜病检测试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
JP7224690B2 (ja) | 2023-02-20 |
JP2022524775A (ja) | 2022-05-10 |
KR20200107858A (ko) | 2020-09-16 |
US20220146531A1 (en) | 2022-05-12 |
CN113544513A (zh) | 2021-10-22 |
AU2020232805A1 (en) | 2022-01-20 |
EP3955001A1 (en) | 2022-02-16 |
AU2020232805B2 (en) | 2024-03-07 |
EP3955001A4 (en) | 2022-12-21 |
KR102309635B1 (ko) | 2021-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020180146A1 (ko) | 당뇨망막병증 진단용 복합 마커 및 이의 용도 | |
KR101286833B1 (ko) | 편평상피세포암 관련 항원을 지표로 하는 피부 성상의 평가방법 | |
JP4677545B2 (ja) | 多量体アディポネクチンの分別測定方法 | |
Pollreisz et al. | Quantitative proteomics of aqueous and vitreous fluid from patients with idiopathic epiretinal membranes | |
WO1991016628A1 (en) | Purification, detection and methods of use of protease nexin-2 | |
WO2020190081A1 (ko) | 실명 유발 주요 안질환 진단용 혈액 마커 및 이를 이용한 진단 방법 | |
WO2020179953A1 (ko) | 당뇨망막병증 진단용 복합 마커 및 이의 용도 | |
WO2020180147A2 (ko) | 나이관련 황반변성 진단용 복합 마커 및 이의 용도 | |
KR100884487B1 (ko) | 인자 ⅶ-활성화 프로테아제의 돌연변이체 및 특이적 항체를 포함하는 진단학적 조성물 | |
WO2020213969A2 (ko) | 각막 내피 세포의 기능 부전 진단용 바이오마커 | |
WO2020189821A1 (ko) | 실명 유발 주요 안질환 진단용 혈액 마커 및 이를 이용한 진단 방법 | |
WO2020166992A1 (ko) | 암의 진단용 조성물 | |
Teráz-Orosz et al. | A new ELISA method for the measurement of total α2-plasmin inhibitor level in human body fluids | |
Narbutt et al. | Pathogenic activity of circulating anti-desmoglein-3 autoantibodies isolated from pemphigus vulgaris patients | |
Yang et al. | Extravasation of plasma proteins can confound interpretation of proteomic studies of brain: a lesson from apo AI in mesial temporal lobe epilepsy | |
WO2020179954A1 (ko) | 나이관련황반변성 진단용 복합 마커 및 이의 용도 | |
WO2017086703A1 (ko) | 나이관련 황반변성 또는 당뇨망막병증 진단용 바이오마커 및 이를 이용한 진단 방법 | |
WO2021104094A1 (zh) | 一种神经退行性疾病标志物Chromogranin B及其应用 | |
WO2022231386A1 (ko) | 위암의 예후 예측 방법 | |
WO2021172923A1 (ko) | 암의 진단용 조성물 | |
Cagnone | INVESTIGATING THE PROTEASE/ANTIPROTEASE BALANCE IN BRONCHOALVEOLAR LAVAGE OF LUNG TRANSPLANT RECIPIENTS THROUGH A MULTIFACTORIAL APPROACH | |
Richardson | Identification and characterisation of novel plasma clot components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20767270 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021553338 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020767270 Country of ref document: EP Effective date: 20211007 |
|
ENP | Entry into the national phase |
Ref document number: 2020232805 Country of ref document: AU Date of ref document: 20200306 Kind code of ref document: A |